Literature DB >> 25534992

Kidney cancer: Inhibition of TK better than mTOR.

Clemens Thoma.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25534992     DOI： 10.1038/nrurol.2014.351

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

Authors:  R Elaidi; A Harbaoui; B Beuselinck; J-C Eymard; A Bamias; E De Guillebon; C Porta; Y Vano; C Linassier; P R Debruyne; M Gross-Goupil; A Ravaud; M Aitelhaj; G Marret; S Oudard
Journal:  Ann Oncol       Date:  2014-12-01       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.